PubRank

Same-day Antiretroviral Therapy With BIC/F/TAF

Clinical Trial ID NCT04712058

PubWeight™ 0.00‹?›

🔗 Visit the ClinicalTrials.gov page for NCT04712058

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection. N Engl J Med 2015 15.06
2 Retention in HIV care between testing and treatment in sub-Saharan Africa: a systematic review. PLoS Med 2011 11.05
3 A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa. N Engl J Med 2015 5.30
4 Antiretroviral Therapy for the Prevention of HIV-1 Transmission. N Engl J Med 2016 3.71
5 Initiating Antiretroviral Therapy for HIV at a Patient's First Clinic Visit: The RapIT Randomized Controlled Trial. PLoS Med 2016 1.81
6 Comparative evaluation of the Bio-Rad Geenius HIV-1/2 Confirmatory Assay and the Bio-Rad Multispot HIV-1/2 Rapid Test as an alternative differentiation assay for CLSI M53 algorithm-I. J Clin Virol 2013 1.29
7 Angiotensinogen's role in ANG formation, renin release, and renal hemodynamics in isolated perfused kidney. Am J Physiol 1989 0.86
8 Effects of a multicomponent intervention to streamline initiation of antiretroviral therapy in Africa: a stepped-wedge cluster-randomised trial. Lancet HIV 2016 0.84
9 The Effect of Same-Day Observed Initiation of Antiretroviral Therapy on HIV Viral Load and Treatment Outcomes in a US Public Health Setting. J Acquir Immune Defic Syndr 2017 0.83
10 Evaluation of the Bio-Rad Geenius HIV 1/2 Confirmation Assay as an Alternative to Western Blot in the Korean Population: A Multi-Center Study. PLoS One 2015 0.77
11 Comparison of a conventional HIV 1/2 line immunoassay with a rapid confirmatory HIV 1/2 assay. J Virol Methods 2014 0.76
12 Effect of immediate initiation of antiretroviral therapy on risk of severe bacterial infections in HIV-positive people with CD4 cell counts of more than 500 cells per μL: secondary outcome results from a randomised controlled trial. Lancet HIV 2017 0.75
13 Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial. Lancet 2017 0.75
Next 100